Skip to content

Iain Redford

Partner - Corporate & financing

Iain’s practice covers a range of industries and he has particular experience in technology and life sciences sectors. His clients include listed companies WPP plc, who he has advised for many years on M&A and investment transactions, IP Group plc, the leading UK life sciences investor, Capgemini plc and Abingdon Health plc, having recently advised them on their AIM IPO, as well as many fast growing UK and international businesses including Oxehealth and Blue Diamond.

Many of the deals Iain works on are cross-border and recent experience includes:

  • Advising Dutch based private equity group Waterland on its acquisition finance facility for the Priory Group purchase
  • DeepMatter Group plc on its acquisition of German based Infochem, and its associated secondary offering
  • US based Accel-KKR’s investment in SaaS group Safeguard and the sale of Vantage Power to US listed group Allison Transmission
  • Advising the tech transfer subsidiaries of three academic institutions (Imperial College Innovations Ltd, UCL Business Ltd, Cambridge Enterprise Ltd) and IP Group on the $145 million funding deal of biotech company Apollo Therapeutics

Credentials

  • BA Law, University of Oxford
  • Qualified 1996
  • Partner 2003
  • Joint Managing Partner 2010 – 2016
  • Head of Corporate 2018 – present
  • Senior Partner 2020 – 2023

What others say

"Leading the team is Iain Redford, whose areas of expertise include mergers and acquisitions, IPOs, financings, and joint ventures. Redford regularly advises multinational technology and life sciences businesses on high-value multijurisdictional deals." Legal 500 2025
“Extensive experience in M&A, IPOs, financing, and joint ventures, particularly in the technology and life sciences sectors.” Legal 500 2024
“Iain Redford offers extensive experience in dealing with M&A, IPOs, financings and joint ventures within the technology and life sciences sectors.” Legal 500 2023
"Iain Redford is a key figure for TMT and life sciences deals." Legal 500 2022
“Bristows was a valued partner in the success of making our vision become a reality.” Stephanie Morris, Director of Industry Partnerships and Commercialisation at Imperial College London
“They enabled a very positive conclusion to the overall deal.” Richard Fagan, Director of BioPharma at UCL Business
“Their expertise made them the perfect partner to work with on the highly complex Apollo transaction.” Richard Fagan, Director of BioPharma at UCL Business
“UCLB has worked with Bristows for over 25 years, in relation to intellectual property licensing transactions as well as corporate transactions such as spinout formation.” Richard Fagan, Director of BioPharma at UCL Business
“Bristows’ knowledge of the life sciences market and players, as well as their licensing expertise, was invaluable as we navigated this complex transaction.” Iain Thomas, Cambridge Enterprise’s Head of Life Sciences

Recommended For

M&A: Smaller Deals, £10m-£100m

Venture Capital

M&A: smaller deals up to £50m

Related Articles